Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.85
-1.3100-2.84%
Pre-market: 45.991.14+2.54%04:11 EDT
Volume:859.92K
Turnover:38.70M
Market Cap:2.75B
PE:10.60
High:46.06
Open:45.96
Low:44.27
Close:46.16
Loading ...

Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $57 From $53

THOMSON REUTERS
·
04 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro

Reuters
·
03 Mar

Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential

TIPRANKS
·
03 Mar

Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook

TIPRANKS
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 12.13% as Blood Cancer Drug Rusfertide Succeeds in Phase 3 Trial, Meeting All Key Endpoints

Stock Track
·
03 Mar

Protagonist Therapeutics Shares up 9.8% as Blood Cancer Treatment Succeeds Late-Stage Study

THOMSON REUTERS
·
03 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, SolarEdge ,Protagonist

Reuters
·
03 Mar

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live
·
03 Mar

BUZZ-Protagonist climbs as blood cancer treatment succeeds late-stage study

Reuters
·
03 Mar

BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Reuters
·
03 Mar

Stock Track | Protagonist Therapeutics Soars 6.41% Pre-Market as Rusfertide Succeeds in Phase 3 PV Trial

Stock Track
·
03 Mar

Protagonist Therapeutics Inc - Rusfertide Generally Well Tolerated With No New Safety Findings

THOMSON REUTERS
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results From Phase 3 Verify Study of Rusfertide in Patients With Polycythemia Vera

THOMSON REUTERS
·
03 Mar

Protagonist Therapeutics Inc - Study Meets Primary Endpoint With Higher Clinical Responders on Rusfertide

THOMSON REUTERS
·
03 Mar

Protagonist Therapeutics Inc - All Four Key Secondary Endpoints Met in Verify Study

THOMSON REUTERS
·
03 Mar

Protagonist Therapeutics Inc - Impact on Takeda's FY2024 Financial Results Is Immaterial

THOMSON REUTERS
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire
·
03 Mar

Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships

TIPRANKS
·
28 Feb

Protagonist Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Protagonist Therapeutics Reports Strong 2024 Financial Results

TIPRANKS
·
25 Feb